NCT03480165View on ClinicalTrials.gov

The Efficacy of 20 mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 20, 2016

Primary Completion Date

September 19, 2017

Study Completion Date

September 19, 2017

Conditions
Anesthesia; FunctionalAnesthesia
Interventions
DRUG

Parecoxib 20 MG/ML

1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)

DRUG

Ropivacaine

19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline

Trial Locations (1)

15350

Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian

All Listed Sponsors
lead

Universiti Sains Malaysia

OTHER

NCT03480165 - The Efficacy of 20 mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery | Biotech Hunter | Biotech Hunter